Narrow By

Press releases

1 2 3 31

BD Launches Enhanced Antimicrobial Stewardship Analytics Capabilities

Nov 21, 2019

FRANKLIN LAKES, N.J., Nov. 21, 2019 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its latest advancement in combating antimicrobial resistance.

BD Empowers Surgeons with a New Technology to Help Simplify Minimally Invasive Ventral Hernia Mesh Placement

Nov 19, 2019

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the U.S. Food and Drug Administration has granted 510(k) clearance for the Phasix ST Mesh with Echo 2 Positioning System for use in abdominal hernia repair.

BD Unveils New Automated Preparation Solution for Microbial Identification

Nov 18, 2019

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced availability in Europe (CE marked) and Canada for the BD Kiestra IdentifA system.

BD Submits Pre-Market Approval Supplement to FDA for BD Onclarity HPV Test with Extended Genotyping Capabilities

Nov 12, 2019

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity HPV Assay.

BD Announces Results for 2019 Fourth Fiscal Quarter and Full Year; Provides Fiscal 2020 Guidance

Nov 5, 2019

BD Announces Results for 2019 Fourth Fiscal Quarter and Full Year; Provides Fiscal 2020 Guidance

BD and Check-Points Receive FDA Clearance for Molecular Screening Test to Detect Antibiotic-Resistant Bacteria

Oct 29, 2019

BD and Check-Points Receive FDA Clearance for Molecular Screening Test to Detect Antibiotic-Resistant Bacteria

BD Expands Single Cell Portfolio with Combined Whole Transcriptome and Protein Analysis Solution for High Dimensional Immunology Research

Oct 28, 2019

BD announced the availability of BD Rhapsody WTA Amplification kit for single-cell analysis on the BD Rhapsody system.

BD Announces Publication of an Independent Analysis of Drug-Coated Balloon Safety Data for Femoropopliteal Peripheral Arterial Disease

Sep 28, 2019

BD announced the publication of a company-initiated, independent analysis of the LUTONIX® 035 Drug Coated Balloon (DCB) femoropopliteal clinical program in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

BD Announces Leadership Succession Plan

Sep 26, 2019

BD Announces Leadership Succession Plan Thomas E. Polen Appointed Chief Executive Officer, Effective Jan. 28, 2020 Vincent A. Forlenza to Continue as Executive Chairman of the Board

Community Clinics Receive Grant for Point-of-Care Diagnostics

Sep 19, 2019

As part of a continued effort to support and improve evidence-based care in community clinics, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, in conjunction with Heart to Heart International (HHI) and the National Association of Free and Charitable Clinics (NAFC) today announced product-based grants to six clinics across the U.S. through the Point of Care, Enhancing Clinical Effectiveness (PoCECE) program.

1 2 3 31

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.